Valuation: OSE Immunotherapeutics

Market Cap 78.32M 90.55M 73.14M 67.1M 126M 8.62B 128M 858M 337M 4.32B 340M 333M 14.28B P/E 2026 *
-2.56x
P/E 2027 * -2.93x
Enterprise Value 119M 138M 111M 102M 192M 13.11B 195M 1.31B 512M 6.57B 517M 506M 21.72B EV / Sales 2026 *
24.3x
EV / Sales 2027 * 13.4x
Free-Float
78.15%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: OSE Immunotherapeutics

1 week+0.94%
Current month+1.38%
1 month-9.82%
3 months-15.17%
6 months-24.87%
Current year-35.94%
1 week 3.09
Extreme 3.092
3.32
1 month 3.09
Extreme 3.092
3.64
3 years 2.65
Extreme 2.65
10.74
5 years 2.65
Extreme 2.65
13.46
10 years 2.65
Extreme 2.65
15.15
Manager TitleAgeSince
Chief Executive Officer - 02/10/2025
Director of Finance/CFO 43 20/08/2025
Chief Tech/Sci/R&D Officer - 20/12/2021
Director TitleAgeSince
Director/Board Member 77 31/05/2016
Director/Board Member 73 14/06/2017
Director/Board Member - 22/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
+2.72%+0.94%-46.00%+13.60% 87.16M
+0.99%+0.35%+4.91%+16.06% 48.7B
+3.71%+6.75%+459.45%+557.32% 42.05B
+2.70%+0.38%+34.49%+10.04% 38.26B
+5.60%+8.13%+16.67%+72.18% 37.5B
+2.21%+4.89%+17.24%+51.64% 31.44B
+2.23%+1.73% - - 16.47B
+0.97%+2.14%+37.25%+128.28% 16.33B
-0.11%+1.75%+8.05%+18.47% 13.98B
+0.75%+14.01%+77.94%+29.28% 12.68B
Average +2.12%+3.06%+67.78%+99.65% 28.6B
Weighted average by Cap. +2.52%+2.31%+98.55%+131.35%

Financials

2026 *2027 *
Net sales 4.9M 5.66M 4.58M 4.2M 7.9M 539M 8.02M 53.69M 21.07M 270M 21.27M 20.81M 893M 10.53M 12.17M 9.83M 9.02M 16.97M 1.16B 17.24M 115M 45.28M 581M 45.71M 44.71M 1.92B
Net income -30.59M -35.36M -28.56M -26.2M -49.28M -3.37B -50.07M -335M -132M -1.69B -133M -130M -5.58B -21.47M -24.82M -20.05M -18.39M -34.59M -2.36B -35.14M -235M -92.32M -1.18B -93.19M -91.15M -3.91B
Net Debt 40.79M 47.16M 38.09M 34.94M 65.73M 4.49B 66.77M 447M 175M 2.25B 177M 173M 7.44B 63.08M 72.93M 58.91M 54.04M 102M 6.94B 103M 691M 271M 3.48B 274M 268M 11.5B
Logo OSE Immunotherapeutics
OSE Immunotherapeutics develops first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). The Company's current well-balanced first-in-class clinical pipeline includes: - Tedopi® (lung cancer vaccine): positive Phase 3 results in NSCLC. Other Phase 2 trials of Tedopi® in combination are ongoing in solid tumors; - OSE-279 (anti-PD1): Phase 1/2 positive results in solid tumors; - OSE-127/Lusvertikimab (humanized monoclonal antibody antagonist of IL-7 receptor): Phase 2 in Ulcerative Colitis. Preclinical research in leukemia; - FR-104/VEL-101 (anti-CD28 mAb): partnership with Veloxis in transplantation; Phase 1/2 in renal transplant (CHU Nantes); - BI 765063/BI 770371 (anti-SIRP? mAb): partnership with Boehringer Ingelheim in advanced solid tumors. OSE Immunotherapeutics expects to generate further significant value from its three proprietary drug discovery platforms: - Pro-resolutive mAb platform focused on targeting and advancing inflammation resolution in I&I; - Myeloid Checkpoint platform focused on optimizing the therapeutic potential of myeloid cells in IO; - Cytokine platform focused on leveraging the Cis-Delivery of cytokine in IO and I&I.
Employees
-
Date Price Change
07/08/26 €3.320 +2.72%
06/08/26 €3.232 -0.55%
05/08/26 €3.250 +1.44%
04/08/26 €3.204 +1.71%
03/08/26 €3.150 -1.19%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.330EUR
Average target price
12.70EUR
Spread / Average Target
+281.38%

Annual profits - Rate of surprise